targeted-delivery
(2)
City Therapeutics
City Therapeutics is a Cambridge, Massachusetts biotechnology company engineering the next generation of RNA interference (RNAi) medicines. Founded by pioneers of the RNAi field, including former Alnylam CEO John Maraganore and Nobel-adjacent academic scientists, the company designs novel siRNA trigger molecules and targeting ligands intended to make RNAi drugs more potent, more specific, and able to reach tissues beyond the liver. Launched in October 2024 with a $135M Series A and backed by a further $99.5M Series B in 2026, City is advancing a pipeline led by CITY-FXI for thromboembolic disease and CITY-RBP4 for Stargardt disease, alongside research collaborations with Biogen and Bausch + Lomb.
AusperBio
AusperBio is a clinical-stage biopharmaceutical company operating in the United States and China that develops antisense oligonucleotide (ASO) therapies aimed at a functional cure for chronic hepatitis B. Built on its proprietary Med-Oligo ASO platform and targeted delivery technology, its lead candidate AHB-137 is an unconjugated ASO advancing into Phase III trials in China, with early data showing a 30% functional cure rate in a subset of patients. Founded in 2019 and headquartered in San Mateo, California, the company has raised over $200 million to date.